Thus, THP1-FRβ tumor-bearing mice were engrafted with a research batch of EGFRt-unsorted E2-CAR-T cells (~23% EGFRt+, 1:1 CD4:CD8) at ~6 million/animal and then treated with 3 different EC17 dosing regimens (Figure 8). Here, CD4 is linked to neoplasm.